Trial Profile

A Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Ascending Single and Multiple Oral Doses of FT2109, Including the Effect of Food, in Healthy Adults

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Oct 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Oct 2026 According to a Forward Therapeutics media release, data from this study has been accepted for presentation at the American College of Rheumatology (ACR) Convergence 2026, taking place November 6-11 in Orlando, Florida.
10 Nov 2025 New trial record
30 Oct 2025 According to Forward Therapeutics media release, the first participant has been dosed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com